<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-02-10">10 February 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Laurent</forename><surname>Calvier</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Pediatric Cardiology and Critical Care</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ekaterina</forename><surname>Legchenko</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Pediatric Cardiology and Critical Care</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lena</forename><surname>Grimm</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Pediatric Cardiology and Critical Care</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hannes</forename><surname>Sallmon</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Neonatology</orgName>
								<orgName type="institution">Charité University Medical Center</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Adam</forename><surname>Hatch</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Chemical Engineering</orgName>
								<orgName type="institution">Northeastern University</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>Massachusetts</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brian</forename><forename type="middle">D</forename><surname>Plouffe</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Chemical Engineering</orgName>
								<orgName type="institution">Northeastern University</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>Massachusetts</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Schroeder</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Institute of Clinical Pharmacology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johann</forename><surname>Bauersachs</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Cardiology and Angiology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Shashi</forename><forename type="middle">K</forename><surname>Murthy</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Chemical Engineering</orgName>
								<orgName type="institution">Northeastern University</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>Massachusetts</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Barnett Institute of Chemical and Biological Analysis</orgName>
								<orgName type="institution">Northeastern University</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>Massachusetts</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Georg</forename><surname>Hansmann</surname></persName>
							<email>hansmann.georg@mh-hannover.de</email>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Pediatric Cardiology and Critical Care</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Cardiology and Critical Care</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Hannover Medical School</orgName>
								<address>
									<addrLine>Carl-Neuberg-Str. 1</addrLine>
									<postCode>30625</postCode>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-02-10">10 February 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">5F1FC0B33592234E9DBDB70A16F2A21E</idno>
					<idno type="DOI">10.1136/heartjnl-2015-308365</idno>
					<note type="submission">Received 5 July 2015 Revised 31 October 2015 Accepted 6 November 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background Several studies have identified circulating biomarkers to be associated with the presence and severity of pulmonary arterial hypertension (PAH).</s><s>Recent evidence supports a role for galectin-3 (Gal-3) and the mineralcorticoid aldosterone in left ventricular failure.</s><s>However, studies on aldosterone together with Gal-3 in PAH are lacking.</s><s>Objective We investigated a novel Aldosterone-galectin-3 (Gal-3) tandem and several other potential PAH biomarkers and their association with the disease severity.</s><s>Methods A total of 57 patients, 41 with idiopathic PAH.</s><s>(IPAH) and 16 with PAH associated with connective tissue disease (CTD), and 8 age-matched, non-relative controls were studied.</s><s>Gal-3, aldosterone and other potential protein plasma concentrations were measured by single ELISA and multi-array MSD (Meso Scale Discovery) technology.</s><s>Results Gal-3 values were increased in both patients with IPAH (12.2±0.6 ng/mL; p&lt;0.05) and with PAH-CTD (14.1 ±1.6 ng/mL; p&lt;0.05) versus control (8.5±0.9 ng/mL), while aldosterone was significantly elevated in IPAH only (248.5 ±38.8 pg/mL vs control 71.9±18.2</s><s>pg/mL; p&lt;0.05).</s><s>In addition, aldosterone, Gal-3, and N-terminal pro-brain natriuretic peptide (NT-proBNP) values were all higher in patients in WHO functional class II-III versus PAH functional class I or controls.</s><s>The vascular injury marker intercellular adhesion molecule 1 (ICAM-1) was increased in IPAH and PAH-CTD versus controls (559.5±18.2</s><s>pg/mL and 734.1 ±59.4 pg/mL vs controls 394.8±39.3</s><s>pg/mL, p&lt;0.05, p&lt;0.0001, respectively), whereas vascular cell adhesion molecule 1 (VCAM-1) and proinflammatory, anti-angiogenic interleukin-12 (IL-12) were elevated in PAH-CTD only (879.5±110.0</s><s>pg/mL and 391.2±70.3</s><s>pg/mL vs controls 489.8±44.6 pg/mL, p&lt;0.01, and 102.1±15.2</s><s>pg/mL, p&lt;0.01, respectively).</s><s>Conclusions Heightened Gal-3 and aldosterone plasma concentrations in PAH patients indicate a role for Gal-3 signalling in the pathobiology of IPAH and PAH-CTD, and may serve as biomarkers for functional status and progression of disease.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>2]<ref type="bibr" target="#b7">[3]</ref> None of the current therapies has been shown to be universally effective, nor have these therapies been able to reverse advanced pulmonary vascular disease or to prevent right heart failure in advanced PAH. <ref type="bibr">2 3</ref> The progressive nature and heterogeneous aetiology of PAH underlines the critical need for both early diagnosis and accurate stratification to allow tailored, efficient therapies. <ref type="bibr" target="#b8">4</ref></s><s>everal studies have identified circulating biomarkers associated with PAH, including markers of endothelial dysfunction, vascular injury and remodelling, myocardial damage, inflammation, and oxidative stress.</s><s>N-terminal pro-brain natriuretic peptide (NT-proBNP), endothelin-1, interleukin-6, interferon-α, C reactive protein (CRP), serotonin, as well as endothelial progenitor cells, and recently identified pulmonary hypertension (PH)-relevant microRNAs, belong to the most validated markers. <ref type="bibr">5 6</ref></s><s> role for aldosterone in pulmonary vascular remodelling and fibrosis has been suggested by increased plasma and tissue concentrations of aldosterone in experimental models, and also in patients with PAH.</s><s><ref type="bibr" target="#b11">[7]</ref><ref type="bibr" target="#b13">[8]</ref><ref type="bibr" target="#b14">[9]</ref><ref type="bibr" target="#b15">[10]</ref> Aldosterone contributes to the activation of pathways that decrease bioavailable nitric oxide levels, induce inflammation, and promote cell proliferation, migration, extracellular matrix remodelling, and fibrosis.</s><s>Moreover, clinical mineralocorticoid receptor (MR) blockade in addition to endothelin-1 receptor inhibition has been associated with a better prognosis in clinical PAH.</s><s><ref type="bibr" target="#b16">11</ref> The molecular mechanisms by which aldosterone exerts its cardiovascular effects are complex.</s><s><ref type="bibr" target="#b17">12</ref> Recent evidence indicates a critical role for galectin-3 (Gal-3), a β-galactoside-binding lectin, in inflammation, fibrosis, and heart failure, downstream of aldosterone.</s><s><ref type="bibr">13 14</ref> Accordingly, Gal-3 is already established as a biomarker for cardiac fibrosis, and chronic left ventricular heart failure.</s><s><ref type="bibr" target="#b20">15</ref>  <ref type="bibr" target="#b21">16</ref> Consequently, Gal-3 has been approved by the US Food and Drug Administration as a new biomarker for additive risk stratification in heart failure, and received a class IIb recommendation in the most recent American Heart Association/American College of Cardiology (AHA/ACC) guidelines.</s><s><ref type="bibr" target="#b22">17</ref> However, to date, combined clinical studies on the role of both Gal-3 and aldosterone in PAH are lacking.</s><s>Here, we investigate several biomarkers in PAH associated with vascular injury and myocardial fibrosis, and identify Gal-3 and aldosterone as potential tandem biomarkers in patients with idiopathic PAH (IPAH) or PAH associated with connective tissue disease (PAH-CTD).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p><s>During the research conferences of the Pulmonary Hypertension Association in California (2010) and  <ref type="figure" target="#fig_0">1E, F</ref>).</s><s>Subsequently, we evaluated whether plasma concentrations of aldosterone, Gal-3, and NT-proBNP differed between PAH patients, grouped by WHO FC (FC I, n=10; FC II-III, n=53).</s><s>Only one patient fulfilled the criteria for WHO FC IV and was, therefore, excluded from the analysis.</s><s>Aldosterone, Gal-3, and NT-proBNP concentrations were all significantly increased in FC II-III PAH versus controls.</s><s>A significant difference between FC II-III and FC I PAH was found only for Gal-3 and NT-proBNP but not for aldosterone plasma concentrations (figure <ref type="figure" target="#fig_1">2A-B, C-D, E-F, respectively</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other markers of vascular injury and inflammation</head><p><s>For our analysis we used several panels of the Meso Scale Discovery's Multi-Array assays in control (n=5), IPAH (n=41), and CTD (n=16) plasma.</s><s>Quantitative measurements were considered reliable when more than 50% of the measurements fell within the linear range of the respective standard curves.</s><s>Such markers included intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), serum amyloid A (SAA), CRP, interleukin-12 (IL-12), fibroblast growth factor 2 (FGF-2) (figure <ref type="figure" target="#fig_2">3</ref>), as well as interleukin-16 (IL-16), vascular endothelial growth factor (VEGF), VEGF-C, and VEGF-D (figure <ref type="figure" target="#fig_3">4</ref>).</s><s>Plasma ICAM-1 concentrations were increased in patients with IPAH and PAH-CTD versus controls (559.5±18.2</s><s>pg/mL and 734.1±59.4</s><s>pg/mL vs controls 394.8±39.3</s><s>pg/mL, p&lt;0.05, p&lt;0.0001, respectively).</s><s>Of note, the average plasma ICAM-1 concentration was significantly higher in PAH-CTD than in IPAH patients (p&lt;0.01;</s><s>figure <ref type="figure" target="#fig_2">3A</ref>).</s><s>In addition, VCAM-1 and IL-12 values were elevated in PAH-CTD patients versus controls (879.5±110.0</s><s>pg/mL and 391.2±70.3</s><s>pg/mL vs controls 489.8±44.6 pg/mL, p&lt;0.01, and 102.1±15.2</s><s>pg/ mL, p&lt;0.01, respectively; figure <ref type="figure" target="#fig_2">3B, E</ref>), but not in IPAH patients.</s><s>The vascular injury/inflammatory markers SAA and CRP plasma concentrations tended to be higher in IPAH and PAH-CTD versus controls (ns; figure <ref type="figure" target="#fig_2">3C, D</ref>).</s><s>FGF-2, that has  previously been shown to be involved in the pathobiology of PAH, 18 also showed a trend toward increased plasma concentrations in IPAH patients versus controls (ns; figure <ref type="figure" target="#fig_2">3F</ref>).</s><s>For the other protein biomarkers measured in PAH and control plasma (IL-16, VEGF, VEGF-C, VEGF-D), no statistically significant differences or clear trends were found (figure <ref type="figure" target="#fig_3">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>Biomarkers hold the potential to provide valuable insights into the pathobiology and disease progression of PAH-a heterogeneous, fatal disease leading to pressure overload and ultimately failure of the right ventricle.</s><s>Prior biomarker studies identified several plasma proteins being altered in PAH. <ref type="bibr" target="#b24">19</ref></s><s>However, none of these molecules exhibited all characteristics of an ideal biomarker (eg, high specificity and sensitivity, correlation with disease progression and therapy, etc).</s><s>Thus, a multiparameter approach has been proposed to adequately reflect the complex and diverse pathogenetic mechanisms of clinical PAH. <ref type="bibr" target="#b10">6</ref></s><s>his is the first report to show that both plasma aldosterone and Gal-3 are increased in PAH, associated with WHO functional class, thus pointing to the potential of aldosterone/Gal-3 to indicate disease severity.</s><s>Gal-3 is involved in several pathological and physiological processes-for example, the regulation of organ development, immune reactions, tumorigenesis, tumour growth, and metastasis. <ref type="bibr" target="#b25">20</ref></s><s>In the heart, Gal-3 augments fibrosis and modulates immune responses, which confers to maladaptive cardiac remodelling. <ref type="bibr" target="#b26">21</ref></s><s>Extracellular matrix remodelling is a key component of fibrosis, and increased Gal-3, which is released by macrophages, is likely to reflect profibrotic activity. <ref type="bibr" target="#b26">21</ref></s><s>ince advanced pulmonary hypertensive vascular disease is characterised by the development of vascular and cardiac fibrosis, increased Gal-3 concentrations in PAH may reflect vascular and right ventricular fibrosis. <ref type="bibr" target="#b27">22</ref></s><s>al-3 is activated by aldosterone in vascular smooth muscle cells of the systemic circulation. <ref type="bibr" target="#b18">13</ref></s><s>Here, we demonstrate that aldosterone is significantly increased in IPAH, but not in PAH-CTD patients, indicating the involvement of aldosterone-independent pathways in CTD, for example, inflammation-mediated induction of Gal-3, possibly mediated by VCAM-1 and IL-12 (figure <ref type="figure" target="#fig_1">2</ref>). <ref type="bibr" target="#b25">20</ref></s><s>Independently of the aldosterone pathway, Gal-3 is expressed by activated macrophages and endothelial cells, attracting inflammatory cells and inducing fibrosis. <ref type="bibr" target="#b25">20</ref></s><s>This aldosterone-independent Gal-3 secretion might be particularly active in PAH-CTD patients.</s><s>Interestingly, we did not find a direct correlation between plasma Gal-3 and aldosterone in IPAH patients.</s><s>Therefore, one might speculate that aldosterone-independent pathways are also relevant in IPAH-associated Gal-3 upregulation.</s><s>However, we provide data from a single time point, so that further studies addressing the temporal courses of aldosterone and Gal-3 values, and their possible correlation, are needed.</s><s>Further limitations of this study include uncontrolled dietary and volume status at the time of plasma acquisition.</s></p><p><s>Both aldosterone and Gal-3 correlated with advanced disease states (as indicated by WHO-FC).</s><s>It is therefore likely that longitudinal assessments of aldosterone and Gal-3 may help identify patients with more advanced PAH.</s><s>Aldosterone can be   targeted by well-established MR antagonists such as spironolactone, which raises the possibility of treating selected patients with aldosterone antagonists. <ref type="bibr">10 23</ref></s><s>In fact, cardiac remodelling and dysfunction appears to be responsive to MR blockade (spironolactone) treatment in clinical studies, such as the ARIES and TOPCAT trials. <ref type="bibr">11 24</ref></s><s>ecause plasma aldosterone is not increased in PAH-CTD, while Gal-3 upregulation is observed in both IPAH and PAH-CTD, PAH patients might benefit from direct Gal-3 blockade.</s><s>These issues therefore need to be addressed in future studies.</s></p><p><s>Beyond the aldosterone/Gal-3 tandem, we found that ICAM-1 was elevated both in IPAH and PAH-CTD versus controls.</s><s>Interestingly, in our study, increased IL-12 and VCAM-1 concentrations were only found in PAH-CTD but not in IPAH patients, which indicates PAH-subtype specific roles for these molecules, probably related to the degree of inflammation, vascular injury and anti-angiogenesis.</s><s>In serum from PAH patients, IL-12 expression values were found to be moderately elevated in IPAH and strongly elevated in PAH-CTD. <ref type="bibr" target="#b30">25</ref></s><s>In contrast, patients with chronic thromboembolic pulmonary hypertension, who do not show perivascular infiltration of T and B lymphocytes in the lungs, had no significant changes in the circulating concentrations of IL-12, indicating that IL-12 elevation is not a direct response to elevated pulmonary arterial pressure. <ref type="bibr" target="#b30">25</ref></s><s>The association of circulating VCAM-1 and ICAM-1 with PH was also reported in patients with sickle cell disease. <ref type="bibr" target="#b31">26</ref></s><s>Knockdown of BMPR-II increased ICAM-1 and VCAM-1 expression in HUVECs (human umbilical vein endothelial cells). <ref type="bibr" target="#b32">27</ref></s><s>These data suggest that VCAM-1 and ICAM-1 induction reflects endothelial activation and dysfunction occurring in PAH.</s></p><p><s>Taken together, we provide evidence for an involvement of Gal-3 and aldosterone in the pathobiology of human PAH and right ventricular dysfunction, and suggest their potential application as a new tandem in clinical PAH.</s><s>This study provides the rationale for further clinical and experimental studies investigating the aldosterone/Gal-3 axis in the pathogenesis of PAH.</s><s>Larger prospective studies including hemodynamics are needed to assess the suitability of aldosterone/Gal-3 as tandem biomarkers for disease progression and treatment response in different PAH aetiologies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key messages</head><p><s>What is already known on this subject?</s><s>The mineralocorticoid receptor agonist aldosterone is involved in pulmonary hypertensive vascular disease and cardiovascular fibrosis.</s><s>We have previously demonstrated in animal models and in vitro that galectin-3 (Gal-3) is a key mediator of cardiac and renal fibrosis induced by aldosterone.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>What might this study add?</head><p><s>This study demonstrates for the first time that the axis aldosterone/galectin-3 (Gal-3) is relevant in pulmonary arterial hypertension (PAH), by showing that plasma levels of both are associated with PAH severity.</s></p><p><s>How might this impact on clinical practice?</s><s>Galectin-3 (Gal-3) is already established as a biomarker for cardiac fibrosis, and chronic left heart failure.</s><s>This work suggest potential applications for aldosterone/galectin-3 (Gal-3) as a new tandem biomarker for clinical PAH.</s></p><p><s>Contributors GH conceived the study, and obtained IRB approval, samples and written consent.</s><s>AH, BDP, HS and SKM participated in the study design, IRB approval and sample collection.</s><s>LC, EL, and LG performed the biochemical assays and statistical analysis.</s><s>LG, HS, and GH structured and analysed the clinical data sets.</s><s>GH and HS wrote the paper.</s><s>HS, LC, EL, JB and GH edited the manuscript.</s></p><p><s>Funding GH currently receives grant support from the German Research Foundation (DFG; HA 4348/2-1), Kinderherzen e.V (W-H-001-2014), and Stiftung KinderHerz</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure1Galectin-3 (Gal-3), aldosterone, and N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma concentrations are elevated in pulmonary arterial hypertension (PAH) patients versus controls.</s><s>The scatter plots on the left and the box and whiskers plots on the right provide data for aldosterone (A and B), galectin-3 (Gal-3) (C and D), and NT-proBNP (E and F) plasma concentrations in control subjects (n=8), patients with idiopathic pulmonary hypertension (IPAH, n=41), and PAH associated with connective tissue disease (CTD, n=16).</s><s>The scatter plots show the mean±SEM; the box and whiskers plots show the median with IQR±10-90th centile.</s><s>*p&lt;0.05,</s><s>**p&lt;0.01.</s></p></div></figDesc><graphic coords="4,206.25,48.42,347.02,366.07" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure2Galectin-3 (Gal-3), aldosterone, and N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma concentrations increase with pulmonary arterial hypertension (PAH) severity.</s><s>The scatter plots on the left and the box and whiskers plots on the right provide data for aldosterone (A and B), galectin-3 (Gal-3) (C and D), and NT-proBNP (E and F) plasma concentrations according to WHO functional classes (FC).</s><s>The scatter plots show the mean±SEM; the box and whiskers plots show the median with IQR±10-90th centile.</s><s>Control, n=8; FC I, n=10; FC II+III, n=53.</s><s>*p&lt;0.05,</s><s>**p&lt;0.01.</s></p></div></figDesc><graphic coords="5,229.27,48.42,324.00,337.89" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Selected potential biomarker plasma concentrations in pulmonary arterial hypertension (PAH) patients.</s><s>The scatter plots provide data for intercellular adhesion molecule 1 (ICAM-1) (A), vascular cell adhesion molecule 1 (VCAM-1) (B), serum amyloid A (SAA) (C), C reactive protein (CRP) (D), interleukin-12 (IL-12) (E), and fibroblast growth factor 2 (FGF-2) (E) plasma concentrations in control subjects (n=5), patients with idiopathic pulmonary hypertension (IPAH, n=41), and connective tissue disease-associated pulmonary hypertension (CTD, n=16).</s><s>Mean±SEM; *p&lt;0.05,</s><s>**p&lt;0.01,</s><s>****p&lt;0.0001.</s></p></div></figDesc><graphic coords="5,228.08,404.73,325.19,342.71" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4</head><label>4</label><figDesc><div><p><s>Figure 4 Selected potential biomarker concentrations in pulmonary arterial hypertension (PAH) patients.</s><s>The scatter plots provide expression level data for interleukin-16 (IL-6) (A), vascular endothelial growth factor (VEGF) (B), VEGF-C (C), and VEGF-D (D) in control subjects (n=5), patients with idiopathic pulmonary hypertension (IPAH, n=41), and connective tissue disease-associated pulmonary hypertension (CTD, n=17).</s></p></div></figDesc><graphic coords="6,217.53,48.42,335.74,216.34" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc><div><p><s>Characteristics of control subjects and PAH patients studied</s></p></div></figDesc><table><row><cell></cell><cell>Control</cell><cell>PAH (total)</cell><cell>IPAH</cell><cell>CTD</cell></row><row><cell>N</cell><cell>8</cell><cell>57</cell><cell>41</cell><cell>16</cell></row><row><cell>Age (years)</cell><cell>49.3 (33-67)</cell><cell>47.2 (19-77)</cell><cell>44.6 (19-74)</cell><cell>53.8 (28-77)</cell></row><row><cell>Male sex (n)</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Height (m)</cell><cell>1.69</cell><cell>1.63</cell><cell>1.63</cell><cell>1.62</cell></row><row><cell>Weight (kg)</cell><cell>73.7</cell><cell>70.3</cell><cell>69.0</cell><cell>73.5</cell></row><row><cell>BMI (kg/m 2 )</cell><cell>25.8</cell><cell>26.5</cell><cell>25.9</cell><cell>27.0</cell></row><row><cell>Race/ethnicity</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>White</cell><cell>7</cell><cell>32</cell><cell>23</cell><cell>9</cell></row><row><cell>B l a c k</cell><cell>0</cell><cell>2</cell><cell>0</cell><cell>2</cell></row><row><cell>Asian</cell><cell>1</cell><cell>1</cell><cell>0</cell><cell>1</cell></row><row><cell>Hispanic</cell><cell>0</cell><cell>5</cell><cell>5</cell><cell>0</cell></row><row><cell>Other</cell><cell>0</cell><cell>17</cell><cell>13</cell><cell>4</cell></row></table><note><p><s>Values represent the number of subjects or mean values, as appropriate.</s><s>Control subjects were age and gender matched to study subjects.</s><s>BMI, body mass index; CTD, pulmonary arterial hypertension associated with connective tissue disease; IPAH, idiopathic pulmonary arterial hypertension; PAH, pulmonary arterial hypertension.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc><div><p><s>Individual PAH patient characteristics, including medication.</s></p></div></figDesc><table><row><cell>Age (yrs)</cell><cell>Weight (kg)</cell><cell>BMI (kg/m 2 )</cell><cell>WHO Class</cell><cell>Medication*</cell></row><row><cell>Diagnosis †: IPAH</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>63</cell><cell>59</cell><cell>26.2</cell><cell>1</cell><cell>SIL, TREPIN, VAL, O2</cell></row><row><cell>31</cell><cell>70</cell><cell>28.4</cell><cell>1</cell><cell>AMB, SIL, TREPIN, DIG, O2</cell></row><row><cell>33</cell><cell>64</cell><cell>22.7</cell><cell>1</cell><cell>NIF, WAR</cell></row><row><cell>33</cell><cell>57</cell><cell>20</cell><cell>1</cell><cell>SIL, WAR, PPI</cell></row><row><cell>33</cell><cell>91</cell><cell>28,1</cell><cell>1</cell><cell>THY, PRE, TREPIV, O2, intravenous immunoglobuline, IRO, WAR, VEN, AMI, SPI, LIS, TOR, BOS, PPI, TRAM, PRC</cell></row><row><cell>49</cell><cell>59</cell><cell>21,7</cell><cell>1</cell><cell>BOS, FUR, NIF, WAR, SAL, SER</cell></row><row><cell>40</cell><cell>94</cell><cell>34,5</cell><cell>1</cell><cell>AMB, AML, FUR, TAD</cell></row><row><cell>26</cell><cell>58</cell><cell>19,4</cell><cell>1</cell><cell>AML, FUR, SIL, WAR</cell></row><row><cell>41</cell><cell>59</cell><cell>20.9</cell><cell>2</cell><cell>BOS, SIL, NIF, WAR</cell></row><row><cell>50</cell><cell>49</cell><cell>19.9</cell><cell>2</cell><cell>BOS, TAD, ASA, SIM, SER</cell></row><row><cell>47</cell><cell>70</cell><cell>28.4</cell><cell>2</cell><cell>BOS, TREPIV, HCT, WAR, ESC, GAB</cell></row><row><cell>19</cell><cell>54</cell><cell>21.9</cell><cell>2</cell><cell>SIL, TREPIV, FUR, ALD, DIG, WAR, IRO, PPI</cell></row><row><cell>74</cell><cell>84</cell><cell>29.8</cell><cell>2</cell><cell>SIL, THY, WAR, SD, CEL</cell></row><row><cell>50</cell><cell>102</cell><cell>36.1</cell><cell>2</cell><cell>BOS, SIL, FUR, ALD, WAR, FLU, FEX, PPI</cell></row><row><cell>60</cell><cell>75</cell><cell>31.2</cell><cell>2</cell><cell>AMB, TRI, ALD, NAP</cell></row><row><cell>44</cell><cell>61</cell><cell>23.8</cell><cell>2</cell><cell>EPIV, ALD, FLU, BUP, GAB</cell></row><row><cell>38</cell><cell>78</cell><cell>26.1</cell><cell>2</cell><cell>BOS, TAD, TREPIV, FUR</cell></row><row><cell>49</cell><cell>86</cell><cell>30.5</cell><cell>2</cell><cell>AMB, AML, TREPIN, TOR, HCT, PRA, PPI, O2</cell></row><row><cell>31</cell><cell>68</cell><cell>22.2</cell><cell>2</cell><cell>PGI, WAR, ESC, GAB, PPI</cell></row><row><cell>34</cell><cell>51</cell><cell>22.7</cell><cell>2</cell><cell>BOS, SIL, TREPSC, FUR, DIG, IRO, HYD, PRE</cell></row><row><cell>48</cell><cell>68</cell><cell>25</cell><cell>2</cell><cell>AMB, TAD, TREPPO, CAV, WAR, BUM, RIS, PPI, TRAM, HYD, Calcium, CET, TEM, TRA, ALP</cell></row><row><cell>43</cell><cell>88</cell><cell>35</cell><cell>2</cell><cell>BOS, SIL, SPI, FUR, ATO, WAR, ILO</cell></row><row><cell>68</cell><cell>53</cell><cell>19,5</cell><cell>2</cell><cell>NIF, WAR, SIM, FLU, PPI, ASA, ALP, IRO, PRC, COD, RAN</cell></row><row><cell>52</cell><cell>71</cell><cell>27,4</cell><cell>2</cell><cell>BOS, TAD, SPI, FUR, MEF, SIT, LIS, DIG, CLG, DUL, LOV, THY, KCL, FAM</cell></row><row><cell>37</cell><cell>109</cell><cell>33,6</cell><cell>2</cell><cell>TAD, AMB, WAR, CET, RAN, SER, GUA, FLT</cell></row><row><cell>48</cell><cell>66</cell><cell>24,8</cell><cell>2</cell><cell>TREPIN, BOS, DIG, TAD, DIL</cell></row><row><cell>21</cell><cell>61</cell><cell>23</cell><cell>2</cell><cell>SIL, AMB, WAR, DIG, PPI, FUR, SPI, Depo Provera</cell></row><row><cell>31</cell><cell>56</cell><cell>21,9</cell><cell>2</cell><cell>SIL, AMB, TREPPO, PPI, TOP, SOL, DIG</cell></row><row><cell>65</cell><cell>51</cell><cell>24,6</cell><cell>2</cell><cell>NIF, THY, SIL, VYT</cell></row><row><cell>60</cell><cell>66</cell><cell>24,8</cell><cell>2</cell><cell>TREP, AMB, TAD, GAB, DIG, SPI, SER</cell></row><row><cell>39</cell><cell>64</cell><cell>27,7</cell><cell>2</cell><cell>TREP, BOS, FUR, PPI, SPI</cell></row><row><cell>29</cell><cell>56</cell><cell>19,4</cell><cell>2</cell><cell>AMB, TAD, TOP, DAB, FUR, IRO</cell></row><row><cell cols="5">44 FSA, AMT69 38 14 2 75 28,2 2 AMB, DIL, CLO, LIS, MEF, PIO, FUR, RAN, ROS, SIT, AMT, REP, DAB, MET</cell></row><row><cell>45</cell><cell>52</cell><cell>20,3</cell><cell>2</cell><cell>TREPIN, BOS, FUR, WAR</cell></row><row><cell>32</cell><cell>88</cell><cell>34,4</cell><cell>2</cell><cell>PRC, BOS, Calcium, IMB, Immodium, LOR, O2, RAN, THY, TREPIV</cell></row><row><cell>65</cell><cell>84</cell><cell>27,4</cell><cell>2</cell><cell>DIL, RAL, RAN, FLT, BOS, SPI, Finacea, ASA, CLB, CIT, BME, TREPIN</cell></row><row><cell>44</cell><cell>54</cell><cell>19,8</cell><cell>3</cell><cell>SIL, AMB, IMB, EPIV, Calcium, THY, TOR, PPI, DIL, MON, CET, SPI</cell></row><row><cell>38</cell><cell>70</cell><cell>28,4</cell><cell>3</cell><cell>BOS, WAR, NOR, ARG, AML, HCT, SD, MOM</cell></row><row><cell>48</cell><cell>86</cell><cell>37,2</cell><cell>3</cell><cell>EPIV, BOS, TAD, FUR, PPI, IRO, FA</cell></row><row><cell>59</cell><cell>86</cell><cell>31.6</cell><cell>3</cell><cell>AMB, SIL, TREPIN, FUR, ALD, WAR, SIM, IRO, OM3, PPI</cell></row><row><cell>Diagnosis*: CTD</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>50</cell><cell>107</cell><cell>37.9</cell><cell>2</cell><cell>BOS, SIL, DIL, FUR, WAR, O2</cell></row><row><cell>62</cell><cell>64</cell><cell>26.3</cell><cell>2</cell><cell>SIL, MTX, PPI</cell></row><row><cell>77</cell><cell>72</cell><cell>27.1</cell><cell>2</cell><cell>BOS, NIF, HCT, THY, PRED, MTX, OM3</cell></row><row><cell>58</cell><cell>70</cell><cell>27.3</cell><cell>2</cell><cell>TAD, HCT, WAR, IRO</cell></row><row><cell>50</cell><cell>60</cell><cell>26.0</cell><cell>2</cell><cell>AMB, AML, FUR, ALD, DIG, ALL, COL, URS, O2</cell></row><row><cell>51</cell><cell>54</cell><cell>23.4</cell><cell>2</cell><cell>BOS, SIL, DIL, THY, PRED</cell></row><row><cell>52</cell><cell>104</cell><cell>38.2</cell><cell>2</cell><cell>BOS, SIL, TREPIN, FUR, BUM, THY, INS, DUL, PRE</cell></row><row><cell>57</cell><cell>84</cell><cell>30.9</cell><cell>2</cell><cell>NIF, TREPIV, MTX, PRED, FA, PPI</cell></row><row><cell>46</cell><cell>91</cell><cell>36,9</cell><cell>2</cell><cell>SIL, QUE, WAR, TREPIN, PPI, HXC, LOZ</cell></row><row><cell>60</cell><cell>68</cell><cell>22,7</cell><cell>2</cell><cell>TREPIN, AMB, SIL, FUR</cell></row><row><cell>57</cell><cell>52</cell><cell>20,3</cell><cell>2</cell><cell>AMB, FUR, BUP, CIT, PPI, PEN, ZOL, FEX</cell></row><row><cell>57</cell><cell>64</cell><cell>26,0</cell><cell>2</cell><cell>BOS, TAD, FUR, SPI, O2</cell></row><row><cell>40</cell><cell>82</cell><cell>26.8</cell><cell>3</cell><cell>BOS, SIL, AML, TREPIV, FUR, ALD, PRED, LOS, CLO, ATE</cell></row><row><cell>66</cell><cell>83</cell><cell>31.2</cell><cell>3</cell><cell>BOS, SIL, FUR, ALD, THY, LIS, PRED, AZA, PPI, PAR, O2</cell></row><row><cell>28</cell><cell>58</cell><cell>21,8</cell><cell>2</cell><cell>TREPIV, SIL, WAR, HXC, FUR, PRC/OXC, MMF, FLU, THY, PRED, FA, PPI, RAN, ZOL</cell></row><row><cell>50</cell><cell>63</cell><cell>25,2</cell><cell>4</cell><cell>PPI, DOM, SIL, AMB, FUR, AML, FA, PRE, LOR</cell></row><row><cell cols="5">*Medications (prostanoids are in bold): ALD=aldactone PO; ALL=allopurinol PO; AMB=ambrisentan PO; AML=amlodipine PO; ALP=alprazolam PO; AMI=amiloride PO;</cell></row><row><cell cols="5">AMT=amitryptilin PO; ARG=l-arginine PO; ASA=acetylsalicylic acid; ATE=atenolol PO; ATO=atorvastatine PO; AZA=azathioprine PO; AZE=azelastine PO; BME=betamethasone PO;</cell></row><row><cell cols="5">BOS=bosentan PO; BUM=bumetanide PO; BUP=bupropion PO; CAV=carvedilol PO; CET=cetirizine PO; CIC=ciclenosid PO; CIT=citalopram PO; CLB=clobetasol topical; CLG=clopidogrel</cell></row><row><cell cols="5">PO; CLO=clonidine PO; COD=codein PO; COL=colchicin PO; DAB=dabigatranexilat PO; DIG=digoxin PO; DIL=diltiazem; DIP=dipyridamole; DOM=domperidone PO; DUL=duloxetine PO;</cell></row><row><cell cols="5">EPIV=epoprostenol IV; ESC=escitalopram PO; FA=folic acid PO; FAM=famotidin PO; FEX=fexofenadine PO; FLT=fluticasone INH; FLU=fluoxetin PO; FSA=fluticasone/salmeterol INH;</cell></row><row><cell cols="5">FUR=furosemide PO; GAB=gabapentin PO; GUA=guifenesin PO; HCT= hydrochlorothiazide PO; HXC=hydroxychloroquine PO; HYD=hydrocodone; ILO=iloprost INH; IMB=imatinib PO;</cell></row><row><cell cols="5">INS=insulin; IRO=iron PO; LEV=levabuterol INH; LIS=lisinopril PO; LOR=loratadin PO; LOS=losartan PO; LOV=lovastatin PO; MED=medodrine; MEF=metformin PO; MET=metoprolol PO;</cell></row><row><cell cols="5">MMF=mycophenolat-mofetil PO; MOM=mometasone PO; MON=montelukast inhal.; MTX=methotrexate PO; MTZ=metronidazole PO; NIF=nifedipine; NOR=norethindrone PO;</cell></row><row><cell cols="5">O2=oxygen by nasal canula; OM3=omega-3-acid ethyl esters PO; OXC=ocycodon PO; PAR=paroxetine PO; PGI=prostanoid; PPI=proton pump inhibitor PO; PRA=pravastatin PO;</cell></row></table><note><p><s>, AZE, WAR, DIG, FUR, HCT, PPI, MTZ, CIC, O2, PRM, TREPIV, SIL, SPI, TRAM, TRC, LEV PRC=paracetamolo PO; PRE=pregabalin; PRED=prednisone PO; PRM=promethazin PO; QUE= quetiapin PO; RAL=raloxifen PO; RAN=ranitidine PO; RIS=risedronate PO; SAL=salmeterol INH; SD=PH study drug; SER=sertraline PO; SIL=sildenafil PO; SIM=simvastatine PO; SIT=sitagliptin PO; SOL=solifenacinsuccinat PO; SPI=spironolactone PO; TAD=tadalafil PO; TEM=temazepam PO; THY=levothyroxine PO; TOP=topiramat PO; TOR=torsemide PO; TRA=trazodone; TRC=triamcinolon PO; TRAM=tramadole; TREP=trepostinil; TREPIV=trepostinil IV; TREPIN=trepostinil inhal.;</s><s>TREPPO=trepostinil PO ; TREPSC=trepostinil subcutaneously; TRI=triamterene PO; URS=ursodiol PO; VAL=valsartan PO; VEN=venlaxafine PO; VYT=ezetimibe/ simvastatin PO; WAR=warfarin PO; ZOL=zolpidem PO †Clinical Classification of Pulmonary Hypertension (World Symposium on PH; Nice 2013) as described in Simonneau G, J Am Coll Cardiol 2013.</s><s>Parenteral prostacyclin administration (intravenous, inhaled, subcutaneous) in the far right column is indicated in bold letters.</s><s>The definition of WHO functional class of PAH can be found in Rubin LJ.</s><s>Diagnosis and management of pulmonary arterial hypertension: ACCP Evidence-Based Clinical Practice Guidelines.</s><s>Introduction.</s><s>Chest 2004;126:7S-10S.</s><s>BMI, body mass index; CTD, PAH associated with connective tissue disease (WSPH Nice PH category 1.4.1);</s><s>DTI, PAH drug and toxin induced (Nice PH category 1.3); HPAH, heritable PAH (Nice PH category 1.2.);</s><s>IPAH, idiopathic PAH (Nice PH category 1.1); IV, intravenous; PAH, pulmonary arterial hypertension; PO, oral; SC, subcutaneous; SSRI, selective serotonin reuptake inhibitor.</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements We thank Dr Paolo Galuppo for his advice on the aldosterone ELISA.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"> (2511-6-13)<p><s>. LC is the recipient of a postdoctoral research stipend from the European Section of the Aldosterone Council (ESAC).</s><s>SKM was supported by grant R01 EB009327 from the US National Institutes of Health.</s><s>The contribution of the COST Action ADMIRE BM1301 is acknowledged (JB).</s></p><p><s>Competing interests None declared.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient consent Obtained.</head><p><s>Ethics approval Northeastern University, Boston (IRB # 11-07-19).</s></p><p><s>Provenance and peer review Not commissioned; externally peer reviewed.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<idno type="DOI">10.1136/heartjnl-2015-308365on10</idno>
		<ptr target="http://heart.bmj.com/Heart:firstpublishedas10.1136/heartjnl-2015-308365on10" />
		<imprint>
			<date type="published" when="2016-02">February 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Calvier</surname></persName>
		</author>
		<idno type="DOI">10.1136/heartjnl-2015-308365</idno>
	</analytic>
	<monogr>
		<title level="j">Heart</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="390" to="396" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">Downloaded from Pulmonary vascular disease on May 17, 2022 by guest</title>
		<idno type="DOI">10.1136/heartjnl-2015-308365on10</idno>
		<ptr target="http://heart.bmj.com/Heart:firstpublishedas10.1136/heartjnl-2015-308365on10" />
		<imprint>
			<date type="published" when="2016-02">May 17. February 2016. February 2016</date>
		</imprint>
	</monogr>
	<note>Protected by copyright. Downloaded from</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Calvier</surname></persName>
		</author>
		<idno type="DOI">10.1136/heartjnl-2015-308365</idno>
	</analytic>
	<monogr>
		<title level="j">Heart</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="390" to="396" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main">Downloaded from Pulmonary vascular disease on May 17, 2022 by guest</title>
		<idno type="DOI">10.1136/heartjnl-2015-308365on10</idno>
		<ptr target="http://heart.bmj.com/Heart:firstpublishedas10.1136/heartjnl-2015-308365on10" />
		<imprint>
			<date type="published" when="2016-02">May 17. February 2016. February 2016</date>
		</imprint>
	</monogr>
	<note>Downloaded from REFERENCES</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Relevant issues in the pathology and pathobiology of pulmonary hypertension</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Tuder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Archer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dorfmüller</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jacc.2013.10.025</idno>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="D4" to="12" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)</title>
		<author>
			<persName><forename type="first">N</forename><surname>Galiè</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Humbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Vachiery</surname></persName>
		</author>
		<idno type="DOI">10.1183/13993003.01032-2015</idno>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="page">317</biblScope>
			<date type="published" when="2015-08-29">2015. 2015 Aug 29</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Pediatric pulmonary hypertension: guidelines from the American Heart Association and</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Abman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hansmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Archer</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00109-011-0779-6</idno>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="2037" to="2099" />
			<date type="published" when="2015">2015</date>
			<publisher>American Thoracic Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Pulmonary arterial hypertension: challenges in translational research and a vision for change</title>
		<author>
			<persName><forename type="first">G</forename><surname>Sutendra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Michelakis</surname></persName>
		</author>
		<idno type="DOI">10.1126/scitranslmed.3005428</idno>
	</analytic>
	<monogr>
		<title level="j">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="208" to="213" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension</title>
		<author>
			<persName><forename type="first">G</forename><surname>Hansmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Plouffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hatch</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00109-011-0779-6</idno>
	</analytic>
	<monogr>
		<title level="j">J Mol Med</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="971" to="983" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Circulating biomarkers in pulmonary arterial hypertension: update and future direction</title>
		<author>
			<persName><forename type="first">B</forename><surname>Pezzuto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Badagliacca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Poscia</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.healun.2014.12.005</idno>
	</analytic>
	<monogr>
		<title level="j">J Heart Lung Transplant</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="282" to="305" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Maron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Leopold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Grover Conference series</title>
				<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title/>
		<idno type="DOI">10.1086/675984</idno>
	</analytic>
	<monogr>
		<title level="j">Pulm Circ</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="200" to="210" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Maron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Opotowsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Landzberg</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurjhf/hfs173</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="277" to="283" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Maron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y-Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>White</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCULATIONAHA.112.094722</idno>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="963" to="974" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Emerging concepts in the molecular basis of pulmonary arterial hypertension: part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Maron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Leopold</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCULATIONAHA.114.006980</idno>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="2079" to="2091" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials)</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Maron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Waxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Opotowsky</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amjcard.2013.04.051</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="720" to="725" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bauersachs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jaisser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Toto</surname></persName>
		</author>
		<idno type="DOI">10.1161/HYPERTENSIONAHA.114.04488</idno>
	</analytic>
	<monogr>
		<title level="j">Hypertension</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="257" to="263" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Galectin-3 mediates aldosterone-induced vascular fibrosis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Calvier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Miana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Reboul</surname></persName>
		</author>
		<idno type="DOI">10.1161/ATVBAHA.112.300569</idno>
	</analytic>
	<monogr>
		<title level="j">Arterioscler Thromb Vasc Biol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="67" to="75" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries</title>
		<author>
			<persName><forename type="first">L</forename><surname>Calvier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Martinez-Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Miana</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jchf.2014.08.002</idno>
	</analytic>
	<monogr>
		<title level="j">JACC Heart Fail</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="59" to="67" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial</title>
		<author>
			<persName><forename type="first">F</forename><surname>Edelmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wachter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Schmidt</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2013.905</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">309</biblScope>
			<biblScope unit="page" from="781" to="791" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial</title>
		<author>
			<persName><forename type="first">F</forename><surname>Edelmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Holzendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wachter</surname></persName>
		</author>
		<idno type="DOI">10.1002/ejhf.203</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="214" to="223" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Yancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jessup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bozkurt</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jacc.2013.05.019</idno>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="e147" to="239" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents</title>
		<author>
			<persName><forename type="first">M</forename><surname>Izikki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Guignabert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fadel</surname></persName>
		</author>
		<idno type="DOI">10.1172/JCI35070</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="512" to="523" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">The potential of biomarkers in pulmonary arterial hypertension</title>
		<author>
			<persName><forename type="first">J-L</forename><surname>Cracowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Leuchte</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amjcard.2012.06.014</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="32S" to="38S" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases</title>
		<author>
			<persName><forename type="first">D</forename><surname>Gruson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ko</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.clinbiochem.2012.04.009</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Biochem</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="719" to="726" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">C</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pokharel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Van Brakel</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.CIR.0000147181.65298.4D</idno>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="3121" to="3128" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Role of galectin-3 in human pulmonary fibrosis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Nishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kawashima</surname></persName>
		</author>
		<idno type="DOI">10.2332/allergolint.O-06-449</idno>
	</analytic>
	<monogr>
		<title level="j">Allergol Int</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="57" to="65" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Aldosterone mediates cardiac fibrosis in the setting of hypertension</title>
		<author>
			<persName><forename type="first">F</forename><surname>Azibani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fazal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chatziantoniou</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11906-013-0354-3</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Hypertens Rep</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="395" to="400" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Anand</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCHEARTFAILURE.113.000887</idno>
	</analytic>
	<monogr>
		<title level="j">Circ Heart Fail</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="104" to="115" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Lack of CCR7 induces pulmonary hypertension involving perivascular leukocyte infiltration and inflammation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">O</forename><surname>Larsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yndestad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sjaastad</surname></persName>
		</author>
		<idno type="DOI">10.1152/ajplung.00048.2010</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Lung Cell Mol Physiol</title>
		<imprint>
			<biblScope unit="volume">301</biblScope>
			<biblScope unit="page" from="L50" to="59" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Martyr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Blackwelder</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2141.2005.05701.x</idno>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="943" to="953" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Anti-inflammatory and antiatherogenic role of BMP receptor II in endothelial cells</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kumar</surname></persName>
		</author>
		<idno type="DOI">10.1161/ATVBAHA.112.300287</idno>
	</analytic>
	<monogr>
		<title level="j">Arterioscler Thromb Vasc Biol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1350" to="1359" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Calvier</surname></persName>
		</author>
		<idno type="DOI">10.1136/heartjnl-2015-308365</idno>
	</analytic>
	<monogr>
		<title level="j">Heart</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="390" to="396" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title/>
		<idno type="DOI">10.1136/heartjnl-2015-308365on10</idno>
		<ptr target="http://heart.bmj.com/Heart:firstpublishedas10.1136/heartjnl-2015-308365on10" />
		<imprint>
			<date type="published" when="2016-02">May 17. February 2016</date>
		</imprint>
	</monogr>
	<note>Downloaded from</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
